Valuation: ProSomnus, Inc.

Market Cap 237K 205K 191K 176K 332K 22.49M 335K 2.24M 881K 11.25M 888K 869K 37.27M P/E 2022
-7.8x
P/E 2023 -0.66x
Enterprise Value 35.24M 30.52M 28.45M 26.17M 49.4M 3.35B 49.96M 334M 131M 1.68B 132M 129M 5.55B EV / Sales 2022
5.49x
EV / Sales 2023 1.85x
Free-Float
90.18%
Yield 2022 *
-
Yield 2023 -
3 years 0
Extreme 0.004
1.69
5 years 0
Extreme 0.004
11.3
10 years 0
Extreme 0.004
11.3
Manager TitleAgeSince
Chief Executive Officer 52 03/05/2022
Chief Tech/Sci/R&D Officer 45 03/05/2022
Director of Finance/CFO 57 01/03/2023
Date Insider Type Main position Quantity % Market Cap.
15/02/24 Free

Founder

315,742 1.9254%
15/02/24 Free

Chief Financial Officer

315,742 1.9254%
15/02/24 Free

Chief Executive Officer

1,322,756 8.0663%
Change 5-day change 1-year change 3-year change Capi.($)
-.--%-.--%-.--%-99.10% 237K
-2.07%+1.68%-22.35%+11.85% 4.18B
-3.36%+10.15%+58.01% - 1.52B
-1.24%+3.16%+21.29% - 703M
+0.39%-2.09%-15.02%-9.33% 148M
+1.32%+2.11%+59.00%+59.00% 117M
+2.86%+27.06%-15.62%-21.74% 58.49M
Average -0.33%+9.28%+12.19%-11.86% 960.65M
Weighted average by Cap. -2.12%+8.11%+2.01%+11.94%

Financials

2022 2023
Net sales 19.39M 16.8M 15.66M 14.4M 27.19M 1.84B 27.49M 184M 72.21M 923M 72.84M 71.23M 3.06B 27.65M 23.95M 22.33M 20.53M 38.76M 2.63B 39.2M 262M 103M 1.32B 104M 102M 4.36B
Net income -7.15M -6.19M -5.77M -5.31M -10.02M -679M -10.13M -67.79M -26.61M -340M -26.84M -26.24M -1.13B -24.1M -20.87M -19.45M -17.89M -33.78M -2.29B -34.15M -229M -89.72M -1.15B -90.5M -88.5M -3.8B
Net Debt 17.17M 14.87M 13.86M 12.75M 24.06M 1.63B 24.33M 163M 63.92M 817M 64.47M 63.05M 2.7B 35.01M 30.32M 28.26M 25.99M 49.07M 3.33B 49.62M 332M 130M 1.67B 131M 129M 5.52B
Logo ProSomnus, Inc.
ProSomnus, Inc. is a medical technology company. The Company is focused on the development, manufacturing and marketing of precision intraoral medical devices, a novel non-invasive option for treating and managing patients with obstructive sleep apnea (OSA). Its intraoral medical devices are engineered to precisely track the treatment plan and anatomy for each patient. The Company's devices have demonstrated efficacy, safety, adherence, and overall outcomes in a growing body of clinical investigations. Its precision intraoral devices are FDA-cleared, patented, and covered by commercial medical insurance, Medicare, TRICARE and many Government-sponsored healthcare plans around the world, representing over 200 million covered lives. The Company’s products include ProSomnus EVO Sleep and Snore Device, ProSomnus EVO SELECT Sleep and Snore Device, ProSomnus EVO [PH] Sleep and Snore Device, ProSomnus [CA] LP Sleep and Snore Device and ProSomnus [MOG] Morning Occlusal Guide.
Employees
136
  1. Stock Market
  2. Stocks
  3. LAAA Stock